71 results about "Primary sequence" patented technology

Compositions, systems and related methods for delivering a supercharged protein or a complex of a supercharged protein and therapeutic agent (e g, nucleic acid, peptide, small molecule) to cells are disclosed. Superpositively charged proteins may be associated with nucleic acids (which typically have a net negative charge) via electrostatic interactions. The systems and methods may involve altering the primary sequence of a protein in order to “supercharge” the protein (e g, to generate a superpositively-charged protein). The compositions may be used to treat proliferative diseases, infectious diseases, cardiovascular diseases, inborn errors in metabolism, genetic diseases, etc.

A media application of some embodiments includes a timeline, which is a composite display area for displaying media clips that are part of the composite media presentation. The timeline of some embodiments includes a primary lane called a spine as well as one or more anchor lanes. The spine represents a primary sequence of media, which, in some embodiments, does not have any gaps. When a clip is deleted or removed from the timeline, the media-editing applications automatically closes the gap created in place of the clip. The clips in the anchor lanes are anchored to a particular position along the spine. Anchor lanes may be used for compositing (e.g., removing portions of one video and showing a different video in those portions), B-roll cuts (i.e., cutting away from the primary video to a different video whose clip is in the anchor lane), audio clips, or other composite presentation techniques.

Engineered binding proteins are provided. In some cases, the parent protein corresponding to the engineered protein has a three-layer swiveling beta/beta/alpha domain. In other cases, the parent protein corresponding to the engineered protein has a rubredoxin-like fold. At least one portion of the primary sequence of the engineered protein is determined by an engineering scheme. In some case, the engineered protein is characterized by an ability to bind to a compound that the parent protein does not bind. In some cases, the parent protein is derived from a domain of a chaperonin or a rubredoxin. One form of engineering scheme used is a randomization scheme. A method for making libraries of engineered proteins, all based on a single parent protein is provided. Methods to identify proteins that bind to compounds of interest in libraries of engineered libraries is provided. An array of engineered proteins immobilized on a support is provided. Each engineered protein in the array is a chaperonin domain or a rubredoxin that has been subjected to an engineering scheme.

The instant invention relates to transgenic non-human animals capable of producing heterologous antibodies, transgenes used to produce such transgenic animals, transgenes capable of functionally rearranging a heterologous D gene in V-D-J recombination, immortalized B-cells capable of producing heterologous antibodies, methods and transgenes for producing heterologous antibodies of multiple isotypes, methods and transgenes for producing heterologous antibodies wherein a variable region sequence comprises somatic mutation as compared to germline rearranged variable region sequences, transgenic nonhuman animals which produce antibodies having a human primary sequence and which bind to human antigens, hybridomas made from B cells of such transgenic animals, and monoclonal antibodies expressed by such hybridomas.

Novel polypeptides having functional domains of interest are described, along with DNA sequences that encode the same. A method of identifying these polypeptides by means of a sequence-independent (that is, independent of the primary sequence of the polypeptide sought), recognition unit-based functional screen is also disclosed. Various applications of the method and of the polypeptides identified are described, including their use in assay kits for drug discovery, modification, and refinement.

The present application relates to novel PEG-G-CSF conjugates in which a PEG molecule is linked to the cyteine residue in position 17 of native G-CSF primary sequence or to the cysteine residue of the corresponding position of a G-CSF analogue. The present application also describes a process for the manufacture of such conjugates, such process comprising the following steps: (i) subjecting the G-CSF protein to conditions inducing reversible denaturation of the protein, (ii) conjugation of the denatured protein obtained is step i with a thiol-reactivc PEG under denaturing conditions, (iii) subjecting the conjugates obtained in step ii to conditions promoting renaturation of the conjugate yielding biologically active G-CSF-PEG conjugate.

The invention discloses a DNA binding protein identification and function annotation deep learning method based on a self-attention mechanism. The method comprises the following steps: selecting a data set from a protein database, training and testing a constructed deep learning model by using the selected data set, and predicting whether protein can be combined with DNA by using the trained deeplearning model, wherein the deep learning model comprises a coding layer, an embedding layer, a long short-term memory neural network layer (LSTM), a convolutional neural network layer (CNN) and a self-attention layer (Self-Attention). Through a deep learning model based on a self-attention mechanism, whether the protein has a function of combining with DNA or not can be predicted according to primary sequence information of the protein, and an area with a combining function is found out.

The invention relates to application of scolopendra mutilans neurotoxin peptide omega-SLPTX-Ssmla, belonging to the field of biomedicine. A primary sequence of the omega-SLPTX-Ssmla comprises 83 amino acid residues, wherein three pairs of disulfide bonds are formed by six aminothiopropionic acids, and the molecular weight is 8811.3 Da. The code of the neurotoxin gene comprises 426 nucleotides of which include signal peptides, premise peptides and mature peptides. The scolopendra mutilans neurotoxin omega-SLPTX-Ssml has a quite obvious enhancement effect on calcium ion channel current on a dorsal ganglion root and is a novel calcium channel agonist. The scolopendra mutilans neurotoxin omega-SLPTX-Ssm provided by the invention can be used for increasing the openness of the calcium channel to enable calcium ions to flow internally and preparing medicaments for treating calcium channel diseases and can also be used as a new tool reagent for calcium channel researches.

The invention provides a rice fertility recovery gene auxiliary breeding molecular marker, which is SNP markers RSRF30121 and FRF4-10-01 respectively co-separated from rice fertility recovery genes Rf3 and Rf4. The marker RSRF30121 is used for detecting a 5606898-th site basic group of an No.1 rice chromosome; the marker FRF4-10-01 is used for detecting a 18838172-th site basic group of an No.10 rice chromosome; primer sequences of the marker RSRF30121 developed on the basis of KASP technology are shown as SEQ ID NO:1-3. Primary sequences of the marker FRF4-10-01 developed on the basis of the KASP technology are shown as SEQ ID NO:4-6. The invention also provides application of the SNP markers RSRF30121 and FRF4-10-01 to rice fertility recovery gene auxiliary breeding. By using the marker combination, whether the rice has the fertility recovery gene or not can be fast identified; important significance is realized on promoting the application of the Rf3 and Rf4 fertility recovery genes to commercial breeding.

In a first step, slot synchronization may be obtained by setting in correlation the received signal with a primary sequence, which represents the primary channel, and storing the received signal. During a second step, the correlator may be re-used for correlating the received signal with a secondary sequence corresponding to the secondary synchronization codes. The correlator may include a first filter and a second filter connected in series, which receive a first secondary sequence and a second secondary sequence, which may include Golay sequences. Architectures of parallel and serial types, as well as architectures designed for reusing further circuit parts are also disclosed. The invention is particularly applicable in mobile communication systems based upon standards such as UMTS, CDMA2000, IS95, and WBCDMA.

Display of peptides or proteins in an ordered, repetitive array, such as on the surface of a virus-like particle, is known to induce an enhanced immune response relative to vaccination with the “free” protein antigen. The 2100 coat proteins comprising the rod-shaped capsid of Tobacco mosaic virus (TMV) can accommodate short peptide insertions into the primary sequence, but the display of larger protein moieties on the virion surface by genetic fusions to the capsid protein has not been possible. Since TMV lacks surface exposed residues compatible with commonly available linker chemistries, we employed a randomized library approach to introduce a reactive lysine at the externally located at the amino-terminus of the coat protein. We found that we could easily control the extent of virion conjugation and demonstrated stoichiometric biotinylation of the introduced lysine. To characterize this modular platform for the display of heterologous proteins, we bound a model antigen (streptavidin (SA)-green fluorescent protein (GFP), expressed and purified from plants) to the surface of TMV, creating a GFP-SA decorated virus particle. Rapid and quantitative determination of the level of TMV capsid decoration was accomplished by subjecting the complex to amino acid analysis and solving the family of linear equations relating the pmoles of each residue to the known amino acid composition of the complex components. We obtained a GFP-SA tetramer loading of 26%, which corresponds to display of approximately 2200 GFP moieties per intact virion. We evaluated the immunogenicity of GFP decorated virions in both mice and guinea pigs, and found augmented humoral IgG titers in both species, relative to unbound GFP-SA tetramer. In mice, we observed a detectable humoral immune response after only a single immunization with the TMV-protein complex. By demonstrating the presentation of whole proteins, this study expands the utility of TMV as a vaccine scaffold beyond that which is possible by genetic manipulation.

Antifreeze polypeptides, antifreeze compositions including the polypeptides, nucleotides encoding the antifreeze polypeptides, methods of making antifreeze compositions, and methods of inhibiting ice crystal growth are provided herein. The peptides are based on the primary sequence of collagen and include those having a molecular weight between about 500-7000 Da. The peptides preferably include cationic polypeptides. The methods of making antifreeze compositions include digesting collagen or gelatin into hydrolysates with peptides having molecular weights between about 500-7000 Da. The digestions are performed with proteases and/or non-enzymatic hydrolysis. The methods of inhibiting ice crystal growth include adding the antifreeze polypeptides or compositions described herein to a composition to be frozen. The methods may be used to inhibit ice crystal growth in frozen food products.

The present invention relates generally to polypeptides whose primary sequence has high sequence homology with human interleukin 2 (IL-2) with some punctual mutations in the sequence of native IL-2. The polypeptides of the present invention have an immunomodulatory effect on the immune system, which is selective/preferential on regulatory T cells. The present invention also relates to specific polypeptides whose amino acid sequence is disclosed herein. In another aspect the present invention relates to pharmaceutical compositions comprising as active ingredient the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their immune modulating effect on diseases such as cancer and chronic infectious diseases.

A method, system, and computer program product to preserve data integrity in a mirror and copy environment is disclosed herein. In one embodiment, a method may include receiving a write command and data from a host device. The method may further include writing the data to a primary storage device and attaching a primary sequence number associated with the primary storage device to the write command, thereby providing a numbered write command with a command sequence number. The numbered write command may then be transmitted to a secondary storage device. The method may further include comparing the command sequence number to a secondary sequence number associated with the secondary storage device. If the command sequence number matches the secondary sequence number, then the command may be executed. Otherwise, it may be ignored.

The invention discloses a preparation method of a fibroin fluorescent probe. The method comprises the following steps: screening a phage library by using a fibroin material to obtain a phage specifically bonded with fibroin proteins; carrying out gene sequencing; using an amino acid sequence corresponding to the gene obtained by sequencing as a fibroin affinity peptide primary sequence; carrying out polypeptide synthesis on the fibroin affinity peptide primary sequence by adopting a polypeptide synthesis technology to obtain fibroin affinity peptide powder; and bonding the fibroin affinity peptide powder with fluorescein to obtain a fibroin fluorescent probe. The phage screened by the invention has very high affinity to the fibroin material, is high in probe sensitivity, high in detection speed and wide in application prospect, and provides more choices for high-efficient targeting and identification of the fibroin protein and the fibroin material.

Methods and apparatus may permit the manipulation of conferenced data. Primary sequenced audio-optical data structures may be populated with conferenced data, and secondary sequenced audio-optical data structures may be populated with derivative conferenced data. Electronic identity characteristics may be utilized to selectively deny access of conference participants to an exchange of conferenced electronic communications, verify the identity of prospective conference participants to an exchange of conferenced electronic communications, and verify the identity of known and unknown individuals in conjunction with electronic identity signatures. Conferenced data tags may be associated to conferenced data elements to create derivative conferenced data. Derivative conferenced data may be utilized in conjunction with primary conferenced data structures and secondary conferenced data structures to create augmented functionalities for conferenced data elements.

The invention discloses an RNA secondary structure prediction method based on a recurrent neural network. The RNA secondary structure prediction method includes the steps: carrying out data preprocessing on an RNA primary sequence data set in a PDB data set; dividing the RNA primary sequence into a long sequence, a medium sequence and a long sequence according to the length; vectorizing the sequence information to obtain feature information expressed in a matrix form, and filling the feature information of the sequence samples unsatisfying the standard by taking the longest sequence information of the long sequence, the medium sequence and the short sequence as the standard to obtain a feature matrix with a fixed dimension; and inputting the feature matrix into an LSTM model established based on a recurrent neural network, and performing RNA secondary structure prediction by using the LSTM model. The RNA secondary structure prediction method based on a recurrent neural network can predict the RNA secondary structure, and the prediction result is relatively accurate, and the implicit features of the RNA sequence can be further mined, and the more accurate RNA secondary structure canbe predicted.